Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
Wehler E, Boytsov N, Nicolay C, Herrera-Restrepo O, Kowal S. Wehler E, et al. Among authors: nicolay c. Pharmacoeconomics. 2020 Jan;38(1):39-56. doi: 10.1007/s40273-019-00829-x. Pharmacoeconomics. 2020. PMID: 31452079 Free PMC article.
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.
Fautrel B, Zhu B, Taylor PC, van de Laar M, Emery P, De Leonardis F, Kannowski CL, Nicolay C, Kadziola Z, De La Torre I, Fleischmann R. Fautrel B, et al. Among authors: nicolay c. RMD Open. 2020 Apr;6(1):e001131. doi: 10.1136/rmdopen-2019-001131. RMD Open. 2020. PMID: 32371431 Free PMC article.
Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
Wehler E, Boytsov N, Nicolay C, Herrera-Restrepo O, Kowal S. Wehler E, et al. Among authors: nicolay c. Pharmacoeconomics. 2020 Jan;38(1):123. doi: 10.1007/s40273-019-00857-7. Pharmacoeconomics. 2020. PMID: 31712980 Free PMC article.
82 results